From: Surgery of highly eloquent gliomas primarily assessed as non-resectable: risks and benefits in a cohort study
mean follow-up (months)
mean overall survival (months)
primary
recurrent
WHO grade I
47.9
-
alive
WHO grade II
38.3
26.0
all alive
WHO grade III
21.6
22.0
20.5
WHO grade IV
8.6
7.9
5.1
6.0